Anti-HeV/NiV Glycoprotein G Antibody (m102.4)

Catalog No.

RVV08002

Expression system

Mammalian Cells

Species reactivity

Hendra virus (isolate Horse/Autralia/Hendra/1994) & Nipah virus

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Applications

ELISA, WB

Target

G, Glycoprotein G, Attachment glycoprotein, Receptor binding protein, RBP

Concentration

1.77 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O89343, Q9IH62

Form

Liquid

Storage buffer

NaAc, 0.2M Arg, pH5.5

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

m102.4

Note

For research use only.

Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding., PMID:18799571

Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses., PMID:19216624

Development of a neutralization assay for Nipah virus using pseudotype particles., PMID:19559943

A catalytically and genetically optimized beta-lactamase-matrix based assay for sensitive, specific, and higher throughput analysis of native henipavirus entry characteristics., PMID:19646266

Targeting of ICAM-1-directed immunoliposomes specifically to activated endothelial cells with low cellular uptake: use of an optimized procedure for the coupling of low concentrations of antibody to liposomes., PMID:20429814

A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system., PMID:21073718

Adaptive immune responses during acute uncomplicated and fulminant hepatitis E., PMID:21143520

A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge., PMID:21689706

Ephrin-B2 and ephrin-B3 as functional henipavirus receptors., PMID:22227101

Henipavirus mediated membrane fusion, virus entry and targeted therapeutics., PMID:22470837

Two distinct lymphocyte homing systems involved in the pathogenesis of chronic inflammatory gastrointestinal diseases., PMID:22572886

Periductal induction of high endothelial venule-like vessels in type 1 autoimmune pancreatitis., PMID:22750968

Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins., PMID:22915804

Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months., PMID:23867060

Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody., PMID:24130486

Henipavirus microsphere immuno-assays for detection of antibodies against Hendra virus., PMID:24508193

Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health., PMID:24572697

Rhabdovirus-based vaccine platforms against henipaviruses., PMID:25320306

Novel Functions of Hendra Virus G N-Glycans and Comparisons to Nipah Virus., PMID:25948743

Structural characterization by transmission electron microscopy and immunoreactivity of recombinant Hendra virus nucleocapsid protein expressed and purified from Escherichia coli., PMID:26196500

The Association of Cytokines and Micronutrients with Hepatitis E Virus Infection During Pregnancy and the Postpartum Period in Rural Bangladesh., PMID:26621563

Protection from Hendra virus infection with Canarypox recombinant vaccine., PMID:29263849

Construction of the safe neutralizing assay system using pseudotyped Nipah virus and G protein-specific monoclonal antibody., PMID:30995971

Rabies-based vaccine induces potent immune responses against Nipah virus., PMID:31016033

Henipavirus-like particles induce a CD8 T cell response in C57BL/6 mice., PMID:31561922

An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections., PMID:31570878

Superinfective Hepatitis E Virus Infection Aggravates Hepatocytes Injury in Chronic Hepatitis B., PMID:31612388

A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection., PMID:31686101

Establishment of a Highly Sensitive Assay for Detection of Hepatitis E Virus-Specific Immunoglobulins., PMID:31694975

Fc-Based Recombinant Henipavirus Vaccines Elicit Broad Neutralizing Antibody Responses in Mice., PMID:32340278

Vaccines to Emerging Viruses: Nipah and Hendra., PMID:32991264

Prediction of the binding interface between monoclonal antibody m102.4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking., PMID:33106487

Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins., PMID:33927387

Sero-Monitoring of Horses Demonstrates the Equivac® HeV Hendra Virus Vaccine to Be Highly Effective in Inducing Neutralising Antibody Titres., PMID:34358146

Architecture and antigenicity of the Nipah virus attachment glycoprotein., PMID:35239409

Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant., PMID:35617431

Serological Hendra Virus Diagnostics Using an Indirect ELISA-Based DIVA Approach with Recombinant Hendra G and N Proteins., PMID:35744614

Development and laboratory evaluation of a competitive ELISA for serodiagnosis of Nipah and Hendra virus infection using recombinant Nipah glycoproteins and a monoclonal antibody., PMID:36816187

Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein., PMID:36932063

A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses., PMID:37243163

Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV., PMID:37577376

Structure and design of Langya virus glycoprotein antigens., PMID:37645760

Prefusion stabilization of the Hendra and Langya virus F proteins., PMID:38214525

Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates., PMID:38569014

Structure and design of Langya virus glycoprotein antigens., PMID:38593070

Measures to prevent and treat Nipah virus disease: research priorities for 2024-29., PMID:38964362

Establishing an immune correlate of protection for Nipah virus in nonhuman primates., PMID:39702562

Functional assessment of the glycoproteins of a novel Hendra virus variant reveals contrasting fusogenic capacities of the receptor-binding and fusion glycoproteins., PMID:39704501

Serological and molecular analysis of henipavirus infections in synanthropic fruit bat and rodent populations in the Centre and North regions of Cameroon (2018-2020)., PMID:39994638

Development and Validation of a Differentiating Infected from Vaccinated Animals (DIVA) Enzyme-Linked Immunosorbent Assay (ELISA) Strategy for Distinguishing Between Hendra-Infected and Vaccinated Horses., PMID:40143282

Document Download

Anti-HeV/NiV Glycoprotein G Antibody (m102.4).pdf